3-stearamidopropyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside | 1144493-18-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-stearamidopropyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside
• 英文别名: 3-Stearamidopropyl 2,3,4,6-tetra-O-benzoyl-alpha-D-glucopyranosyl-(1->4)-2,3,6-tri-O-benzoyl-alpha-D-glucopyranosyl-(1->4)-2,3,6-tri-O-benzoyl-alpha-D-glucopyranosyl-(1->4)-2,3,6-tri-O-benzoyl-beta-D-glucopyranoside；[(2R,3R,4S,5R,6R)-4,5-dibenzoyloxy-3-[(2R,3R,4S,5R,6R)-3,4-dibenzoyloxy-6-(benzoyloxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4-dibenzoyloxy-6-(benzoyloxymethyl)-5-[(2R,3R,4S,5R,6R)-3,4,5-tribenzoyloxy-6-(benzoyloxymethyl)oxan-2-yl]oxyoxan-2-yl]oxyoxan-2-yl]oxy-6-[3-(octadecanoylamino)propoxy]oxan-2-yl]methyl benzoate
• CAS: 1144493-18-4
• 化学式: C₁₃₆H₁₃₅NO₃₅
• 分子量: 2343.55
• InChiKey: JQEATUPOJNACMO-VVJCZCDQSA-N

物化性质

• 密度：
  1.35±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  28.1
• 重原子数：
  172
• 可旋转键数：
  70
• 环数：
  17.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  445
• 氢给体数：
  1
• 氢受体数：
  35

反应信息

• 作为反应物：
  描述：

  3-stearamidopropyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside 在 sodium methylate 、 acidic resin 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 反应 24.0h， 以100%的产率得到3-stearamidopropyl α-D-glucopyranosyl-(1-4)-α-D-glucopyranosyl-(1-4)-α-D-glucopyranosyl-(1-4)-β-D-glucopyranoside
  参考文献：
  名称：

  [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS

  摘要：

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。

  公开号：

  WO2009049370A1
• 作为产物：
  描述：

  、 十八烷酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 72.0h， 生成 3-stearamidopropyl 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-α-D-glucopyranosyl-(1-4)-2,3,6-tri-O-benzoyl-β-D-glucopyranoside
  参考文献：
  名称：

  [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES
  [FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS

  摘要：

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。

  公开号：

  WO2009049370A1

文献信息

• NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES
  申请人：Ferro Vito

  公开号：US20110245196A1

  公开（公告）日：2011-10-06

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  本发明涉及新型化合物，其具有作为肝素硫酸结合蛋白抑制剂的效用；包含该化合物的组合物以及使用该化合物和组合物进行哺乳动物受体的抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。
• Sulfated oligosaccharide derivatives
  申请人：Ferro Vito

  公开号：US08828952B2

  公开（公告）日：2014-09-09

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  本发明涉及新型化合物，其具有作为肝素硫酸结合蛋白抑制剂的功用；包含该化合物的组合物，以及使用该化合物和组合物进行哺乳动物主体的抗血管生成、抗转移、抗炎、抗微生物、抗凝和/或抗血栓治疗的用途。
• SULFATED OLIGOSACCHARIDE DERIVATIVES
  申请人：Progen Pharmaceuticals Limited

  公开号：US20150065440A1

  公开（公告）日：2015-03-05

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  本发明涉及新型化合物，其具有作为肝素硫酸结合蛋白抑制剂的用途；包含该化合物的组合物以及使用该化合物和组合物进行哺乳动物受试者的抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗。
• [EN] METHODS OF PRODUCING SULFATED OLIGOSACCHARIDE DERIVATIVES AND INTERMEDIATES THEREOF<br/>[FR] PROCÉDÉS DE PRODUCTION DE DÉRIVÉS D'OLIGOSACCHARIDE SULFATÉ ET DE SES INTERMÉDIAIRES
  申请人：[en]PROGEN PG500 SERIES PTY LTD

  公开号：WO2022183254A1

  公开（公告）日：2022-09-09

  The invention relates inter alia to methods of producing sulfated oligosaccharide derivatives and intermediates thereof. The sulfated oligosaccharide derivatives may be represented by the following formula (I) wherein: X and Y are any D- or L-hexose or pentose, wherein each hydroxyl group not involved in a glycosidic linkage is substituted by a group W, and Y has an anomeric carbon atom; W is SO3M, and M is any pharmaceutically acceptable cation; n is an integer from 2 to 6; Z is O, and is linked to the anomeric carbon atom of Y; and R1R2together form a lipophilic moiety.
• [EN] NOVEL SULFATED OLIGOSACCHARIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'OLIGOSACCHARIDES SULFATÉS
  申请人：PROGEN PHARMACEUTICALS LTD

  公开号：WO2009049370A1

  公开（公告）日：2009-04-23

  The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.

  这项发明涉及具有作为肝素硫酸结合蛋白抑制剂的效用的新化合物；包含这些化合物的组合物；以及利用这些化合物和组合物对哺乳动物主体进行抗血管生成、抗转移、抗炎、抗微生物、抗凝血和/或抗血栓治疗的用途。